Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Stock Forecast & Price Target

See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
8 Buy
6 Hold
0 Sell
Based on 14 analysts giving stock ratings to
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VRTX Stock Price Prediction

Average Price Target

▼(-0.55% Downside)
Based on 14 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $299.00 with a high forecast of $365.00 and a low forecast of $250.00. The average price target represents a -0.55% change from the last price of $300.64.
Highest Price Target$365.00Average Price Target$299.00Lowest Price Target$250.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Upside / Downside
Upgrade Banner
SVB Securities
We were also encouraged by mgmt.’s discussion of company efforts to increase APOL1 kidney disease awareness, diagnosis, and genotyping which we see as key to enabling commercial success. The company plans to file its cell therapy for sickle cell and beta thalassemia (“exa-cel”) in the EU by YE22 and noted FDA alignment should be reached in “coming weeks.” VRTX discussed phase 3 trial designs for its NaV1.8 pain drug VX-548 that suggest a <1 month timeframe for treatment and follow-up per patient.
J.P. Morgan
JPMorgan assumes Vertex (VRTX) at OverweightJPMorgan analyst Jessica Fye assumes coverage on Vertex (NASDAQ: VRTX) with a Overweight rating and a price target of $319.00.
Cantor Fitzgerald
Cantor Fitzgerald Initiates Coverage On Vertex Pharmaceuticals with Overweight Rating, Announces Price Target of $365
BMO Capital
Vertexs (VRTX) ViaCyte Acquisition "Adds Additional Shots on Goal" - BMO Capital reiterates Stock at Outperform with $325 Price TargetBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $325.00 price target on Vertex (NASDAQ: VRTX), following the companys announcement of ViaCyte acquisition.
Argus Research
Vertex Pharmaceuticals price target raised to $280 from $275 at ArgusVertex Pharmaceuticals price target raised to $280 from $275 at Argus
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

VRTX Stock Forecast FAQ

What is VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is $299.00.
    What is VRTX’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for VRTX, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is VRTX a Buy, Sell or Hold?
        Vertex Pharmaceuticals has a conensus rating of Moderate Buy which is based on 8 buy ratings, 6 hold ratings and 0 sell ratings.
          What is Vertex Pharmaceuticals’s price target?
          The average price target for Vertex Pharmaceuticals is $299.00. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $365.00 ,the lowest forecast is $250.00. The average price target represents -0.55% Decrease from the current price of $300.64.
            What do analysts say about Vertex Pharmaceuticals?
            Vertex Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis